Orrick, Goodwin Steer Bayer's $240M BlueRock Buy

By Adam Rhodes
August 8, 2019, 2:48 PM EDT

Orrick-guided Bayer AG will buy the roughly 60% of Goodwin-led BlueRock Therapeutics it does not already own in a deal that implies a roughly $1 billion value for the biotechnology firm...

Already a subscriber? Click here to view full article